Navigation Links
Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
Date:11/12/2013

LONDON, November 12, 2013 /PRNewswire/ --

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia (IDA) in pre-dialysis patients with chronic kidney disease (CKD).  

ST10 is a novel oral ferric iron therapy being developed for the treatment of iron deficiency which has demonstrated potential as an effective oral alternative to parenteral (IV) iron in ferrous intolerant patients.  Previous clinical studies have shown that gastrointestinal absorption of ST10 is at least as good as ferrous products, however ST10 has minimal gastro-intestinal side effects so can be given on an empty stomach and is therefore given at a significantly lower daily dose.  As ST10 is not adversely affected by changes in gastric pH, it can also be co-prescribed with widely used acid-reducers.

The British National Formulary states: 'parenteral iron does not produce a faster response than oral iron provided the oral iron is taken reliably and is absorbed adequately.'  ST10 aims to deliver this compelling alternative to prescribers, patients and payors, in addition to avoiding the inconvenience, high cost and life-threatening hypersensitivity risks associated with IV infusions.

The 16-week prospective, multicentre, randomised, double-blind, placebo controlled AEGIS 3 study will enrol pre-dialysis CKD patients in the USA who have a diagnosis with iron deficiency anaemia.  ST10 is also currently being investigated in a pivotal Phase 3 study as a potential treatment for IDA in inflammatory bowel disease, top-line results from which are expected towards the end of 2013.

Epidemiology data suggests the current total IDA patient population in the EU, USA and Japan is approximately 34m, with an addressable population of 2.6m (IBD and CKD in the EU and US) in the first instance.  The core market in IDA is worth at least $3.0bn. The global CKD therapeutics market is forecast to grow at a compound annual growth rate (CAGR) of 6.4% to reach $11.6billion by 2018[1].

Carl Sterritt, Founder and Chief Executive Officer of Shield Therapeutics, stated: "We are excited about the market potential of ST10 and the filing of this IND application marks another important milestone in the development of ST10 as we move into a second major indication.  We believe the benefits ST10 will deliver to patients with CKD who cannot tolerate oral ferrous iron therapy, coupled with the convenient nature of its administration, will make ST10 a leader in the future treatment paradigm of IDA in CKD."

[1]Chronic Kidney Disease (CKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018, GlobalData, September 2011

About Shield Therapeutics

Shield Therapeutics (http://www.shieldtherapeutics.com), founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need.  Shield is currently conducting pivotal Phase 3 studies of its lead asset, ST10, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease and is soon to commence a Phase 3 study of ST10 for the treatment of iron deficiency anaemia in patients with chronic kidney disease.

For more information about Shield Therapeutics, please contact:

Consilium Strategic Communications
Mary-Jane Elliott / Emma Thompson/ Lindsey Neville
Tel +44(0)20-7920-2333
Email: shieldtherapeutics@consilium-comms.com



'/>"/>
SOURCE Shield Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Blue Cross Blue Shield of Michigan and Blue Care Network support the Drug Enforcement Administrations Nationwide Prescription "Drug Take-Back Day"
2. Wellness Center USA Inc. Signs Agreement to Acquire Psoria-Shield Inc.
3. Healthcare Expense Management Leader Patientco Receives $3.75M in funding led by BlueCross BlueShield Venture Partners and Sandbox Industries
4. Wellness Center USA, Inc. Completes Psoria-Shield Inc. Acquisition
5. Shield HealthCare Announces 12th Annual Caregiver Story Contest
6. BI-LO Offers Health Giveaways With Flu Vaccinations, Encourages Community To Shield Their Health This Flu Season
7. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
8. Healthcare Fraud Shield Now Offers SIU Services
9. Radiation Detection, Monitoring & Safety Market (Geiger Counter, Ionization Chamber, Scintillator, Terahertz detector, Dosimeter, Environment Monitor, Shield, Lead Apron, Eyewear & Glove) - Competitive Analysis & Global Forecasts to 2017
10. Blue Cross Blue Shield Texas Launches "Be Covered Texas" Campaign to Raise Awareness of Individual Health Insurance Enrollment Options
11. ASSA ABLOY Door Group Announces RF Shielding Openings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology:
(Date:4/28/2017)... Salt Lake City, UT (PRWEB) , ... April 28, 2017 , ... ... that exist in some of their formulas. This begins with the popular ClearLungs Extra ... impacted, they will be changing the formula in the following ways:, ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... http://www.foodsthathealdaily.com , http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to ... of Water, Global Climate Change and Your Health on Voice America sponsored by ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and ... more adverse experiences than children in the general population. That’s because foster care ... or other family challenges. While no fault of their own, youth who have ...
(Date:4/28/2017)... ... , ... People are starting to accept that hearing aids can be helpful ... stigma it had when great-grandpa wore his hearing aids years ago,” said Dr. Maura ... North American Speaker Series (NASS) segment. “He probably wore an iPod-size hearing aid ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer ... East region. Côté has 20+ years of experience within the beauty industry, ranging ... with an array of high-end cosmetic brands, retail brands and outlets in Canada ...
Breaking Medicine News(10 mins):